Corpus ID: 31485654

Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study.

@article{Uygur1998EffectsOT,
  title={Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study.},
  author={M. Uygur and A. I. Arik and U. Altuǧ and D. Erol},
  journal={Steroids},
  year={1998},
  volume={63 4},
  pages={
          208-13
        }
}
  • M. Uygur, A. I. Arik, +1 author D. Erol
  • Published 1998
  • Medicine
  • Steroids
  • In the present study, we investigated the effects of a steroid 5 alpha-reductase inhibitor, finasteride, when given orally (5 mg/day), on the serum levels of gonadal, hypophyseal, and adrenal hormones and the clinical significance of these effects. Forty-eight patients with a mean age of 63 (range 49-81) were included in the study. All patients had symptoms of benign prostatic hyperplasia. Serum levels of testosterone, dihydrotestosterone, follicle-stimulating hormone (FSH) luteinizing hormone… CONTINUE READING
    25 Citations
    Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction
    • 24
    Androgen replacement therapy: present and future.
    • 55
    • PDF
    Androgen Replacement Therapy
    • 28
    The Steroidogenesis Inhibitor Finasteride Reduces the Response to Both Stressful and Rewarding Stimuli
    • 6
    • PDF
    5-alpha reductase inhibitors and erectile dysfunction: the connection.
    • 64
    The role of testosterone in the pathogenesis of prostate cancer
    • 65
    Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.
    • C. Chen, N. Weiss, +5 authors G. Goodman
    • Medicine
    • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
    • 2003
    • 111
    • PDF